Lenalidomide (Revlimid)
Oral immunomodulatory drug for multiple myeloma, MDS, and lymphomas. FDA approved. Oral tablet taken at home.
What is lenalidomide?
What it targets
Cereblon (CRBN), leading to selective degradation of IKZF1 and IKZF3, weakening support for cancer cells and strengthening immune attack on them.
Who it may help
Myeloma patients needing combination therapy or maintenance; del(5q) MDS patients with transfusion-dependent anemia; relapsed lymphoma patients; those with adequate kidney function.
Why testing matters
Baseline blood counts, kidney and liver function, and disease-specific biomarkers (myeloma cytogenetics, lymphoma subtype) guide dose selection and monitor treatment tolerance.
Which cancers can lenalidomide treat?
Lenalidomide is approved for several hematologic malignancies, often as combination therapy. Approval status and use vary by indication and country.
| Multiple myeloma (frontline, relapsed, maintenance) | FDA approved for MM with dexamethasone; also as maintenance after autologous stem cell transplant. Most commonly used in combination with proteasome inhibitors (bortezomib, carfilzomib) and monoclonal antibodies (daratumumab, isatuximab) in NCCN 2026 preferred regimens. |
| Transfusion-dependent MDS with deletion 5q | FDA approved for lower-risk (low or intermediate-1 risk) MDS with del(5q). Lenalidomide improves anemia and reduces transfusion dependence in a subset of patients; response rates around 67%. |
| Mantle cell lymphoma (relapsed/refractory) | FDA approved for MCL after 2 prior therapies including bortezomib. Used as monotherapy or in selected combinations. Less commonly used than in myeloma. |
| Follicular lymphoma (previously treated) | FDA approved in combination with rituximab for previously treated FL. Adds benefit to anti-CD20 therapy in selected patients. |
| Marginal zone lymphoma (previously treated) | FDA approved in combination with rituximab for previously treated MZL. Used in similar fashion to follicular lymphoma combinations. |
Are you eligible for lenalidomide?
Eligibility depends on confirmed cancer diagnosis, disease status, organ function, and disease-specific biomarkers. Your oncologist will assess your complete clinical picture before prescribing.
- Confirmed diagnosis of multiple myeloma, MDS, or lymphoma by biopsy or marrow examination
- Disease-specific biomarkers or cytogenetics reviewed (myeloma cytogenetics, FISH for del(5q), lymphoma subtype)
- Adequate kidney function (dose adjustment required if creatinine clearance <60 mL/min)
- Adequate liver function (hepatic enzyme abnormalities require monitoring)
- Adequate baseline blood counts or plan for close monitoring and possible supportive care
- Ability to follow REMS pregnancy prevention requirements if female or male with reproductive partners
- Willingness to take prophylactic anticoagulation if at high thrombotic risk
How does lenalidomide work?
- Binds to cereblon (CRBN)
- Degrades cancer cell support proteins
- Enhances immune recognition
- Alters bone marrow microenvironment
Lenalidomide is a dual-action drug: it kills cancer cells directly and unleashes immune attack simultaneously.
Tests required before starting lenalidomide
These tests confirm eligibility, guide dosing decisions, and establish baselines for monitoring during treatment.
| Complete blood count (CBC) | Essential to establish baseline hemoglobin, white blood cells, neutrophils, and platelets. Lenalidomide can cause significant hematologic toxicity; baseline counts guide dose decisions. |
| Kidney function tests (serum creatinine, creatinine clearance) | Lenalidomide is cleared renally; dose reduction is mandatory if creatinine clearance <60 mL/min. Even mild renal impairment affects dosing. |
| Liver function tests (AST, ALT, bilirubin, alkaline phosphatase) | Baseline liver function identifies patients at higher risk for drug-related hepatotoxicity. Monitoring continues throughout treatment. |
| Myeloma workup (SPEP, IFIXE, free light chains, calcium, LDH, imaging) | Serum and urine protein electrophoresis, immunofixation, free light chains, and bone disease assessment guide baseline disease burden and prognosis. |
| Cytogenetics and FISH for del(5q) in MDS | In MDS patients, FISH testing for deletion 5q is mandatory for lenalidomide sensitivity. Without del(5q), lenalidomide efficacy is substantially lower. |
| Pregnancy test and contraception planning | Two negative pregnancy tests required for females of childbearing potential before starting. Dual contraception mandatory throughout and 4 weeks after stopping. |
| Thrombosis risk assessment | History of prior DVT, PE, stroke, atrial fibrillation, or other thrombotic events requires escalated anticoagulation strategy during lenalidomide therapy. |
How is lenalidomide given?
Lenalidomide is taken by mouth as capsules in cycles. Dosage and scheduling depend on disease type, indication, and combination regimen. Capsules should be swallowed whole with water.
| Dosage — multiple myeloma (combination therapy, transplant-eligible) | Typically 10-25 mg once daily on days 1-21 of a 28-day cycle, combined with bortezomib and dexamethasone or other partners. Exact dose depends on prior treatment and tolerability. |
| Dosage — multiple myeloma (transplant-ineligible, Len-Dex) | Typically 10-25 mg once daily continuously or on a 21/28 schedule, combined with dexamethasone. Dose adjusted based on side effects and blood counts. |
| Dosage — MDS with del(5q) | 10 mg once daily on days 1-21 of a 28-day cycle. Lower starting dose for renal impairment (5 mg if CrCl <60 mL/min). |
| Dosage — mantle cell lymphoma and follicular lymphoma | Typically 20 mg once daily on days 1-21 of a 28-day cycle, often combined with rituximab or other agents. Adjusted for tolerability and kidney function. |
| How to take | Swallow capsules whole with water. Do not break, chew, or open capsules. Take at the same time each day. May be taken with or without food, but consistency helps maintain steady levels. |
| Timing and missed doses | Take at the same time each day if possible. If you miss a dose, take it as soon as you remember that day. If it is the next day, skip the missed dose and resume your regular schedule. Never double dose. |
| Duration of therapy | In myeloma, lenalidomide is typically continued until disease progression. Maintenance therapy after stem cell transplant may continue for years. In MDS and lymphoma, duration depends on response and tolerability. |
| Kidney function dose adjustments | Creatinine clearance >60 mL/min: standard dose. CrCl 30-59 mL/min: reduce dose to 50% starting dose. CrCl <30 mL/min: reduce to 25% starting dose. Dialysis patients: dose after dialysis only. |
Clinical evidence and benefits
Lenalidomide has been studied extensively in multiple myeloma, MDS, and lymphomas. Benefits vary by disease type and combination used; outcomes represent published clinical trial data.
| Multiple myeloma — progression-free survival | In frontline myeloma, lenalidomide-based combinations (dara-VRd, isa-VRd) achieve median PFS of 4-5 years. Longer than lenalidomide monotherapy or older regimens. |
| Multiple myeloma — response rates | Combination regimens achieve complete response or better in 40-60% of newly diagnosed patients. In relapsed disease, response rates vary by prior exposures and resistance mechanisms. |
| Myeloma maintenance after stem cell transplant | Lenalidomide maintenance prolongs progression-free survival by approximately 2-3 years compared to no maintenance. Median PFS advantage ~3 years in landmark trials. |
| MDS with del(5q) — transfusion independence | Approximately 67% of patients achieve transfusion independence. Cytogenetic complete remission in subset. Benefits durable; median OS improvement demonstrated. |
| Mantle cell and follicular lymphoma | In relapsed MCL, lenalidomide monotherapy achieves response in 25-35% of patients. With rituximab in follicular lymphoma, response rates substantially higher at 70%+ in some trials. |
Individual responses vary. Benefits depend on disease biology, prior treatments, patient factors, and combinations used. These represent published clinical trial results.
Side effects of lenalidomide
Lenalidomide causes hematologic toxicity and constitutional symptoms more commonly than conventional chemotherapy. Most side effects are manageable with supportive care and dose adjustments.
| Neutropenia (low white blood cells) | Very common (>79% in some trials). Severity ranges from grade 1-4. Requires CBC monitoring and possible growth factor support or dose reduction. |
| Thrombocytopenia (low platelets) | Very common (>70%). Often grade 1-3 but can be severe. Requires platelet transfusions in severe cases. Usually reversible with dose reduction. |
| Anemia | Common (20-40%). May require red blood cell transfusions, erythropoietin, or dose adjustment. |
| Fatigue and weakness | Common in 20-40% of patients. Usually manageable; usually improves with time or dose adjustment. Sleep, nutrition, and activity support help. |
| Diarrhea and constipation | Common (30-55% for diarrhea, 20-40% for constipation). Dietary modifications, loperamide, psyllium, or lactulose usually effective. Alternate within a patient. |
| Nausea and reduced appetite | Occurs in 20-30%. Usually mild. Anti-emetics (ondansetron) and small frequent meals help. |
| Rash and itching | Occurs in 20-32%. Usually mild maculopapular. Can be severe (Stevens-Johnson syndrome rare). Antihistamines and topical steroids usually effective. |
| Muscle cramps and joint pain | Occurs in 20-30%. Often in legs. Quinine, stretch, magnesium, or calcium supplementation may help. |
Contact your doctor immediately if you develop:
- Fever (>38.5°C or 101.3°F) — may signal serious infection requiring urgent evaluation
- Severe shortness of breath, chest pain, or leg swelling — may indicate blood clot (DVT or PE)
- Unusual bleeding or bruising, dark stools, or blood in urine — may indicate thrombocytopenia crisis
- Severe rash spreading rapidly, mouth sores, or eye inflammation — may indicate Stevens-Johnson syndrome
- Yellowing of skin or eyes, dark urine, or severe abdominal pain — may indicate liver toxicity
- Confusion, severe dizziness, or signs of stroke (facial drooping, arm weakness, speech difficulty)
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products. Lenalidomide has several important drug interactions and safety considerations.
- Pregnancy and breastfeeding: Lenalidomide causes severe birth defects (Category X). Dual contraception required; never breastfeed.
- Kidney disease: Dose reduction mandatory if creatinine clearance <60 mL/min. Dialysis patients dosed after treatment only.
- Liver disease: Use with caution; monitor liver enzymes closely. Severe hepatic impairment may require dose reduction.
- Prior thrombosis (DVT, PE, stroke, atrial fibrillation): Increased thrombotic risk on lenalidomide. Anticoagulation often recommended.
- Enzyme inducers (carbamazepine, rifampicin, phenytoin): Reduce lenalidomide levels significantly; avoid or use with caution and increased monitoring.
- Warfarin: Significant interaction. Low-molecular-weight heparin (LMWH) is preferred if anticoagulation needed.
- Cytochrome P450 inhibitors: May raise lenalidomide levels. Monitor tolerability carefully.
- Vaccines: Live vaccines should be avoided during lenalidomide therapy. Inactivated vaccines acceptable but may be less effective.
Lenalidomide combination treatments
Lenalidomide is rarely used as monotherapy in current practice. Most regimens combine it with proteasome inhibitors, monoclonal antibodies, and corticosteroids for synergistic benefit.
| Bortezomib, lenalidomide, dexamethasone (VRd) | Longstanding backbone regimen for myeloma. Effective in frontline and relapsed disease. Often superseded by 4-drug combinations (add daratumumab or isatuximab). |
| Daratumumab, bortezomib, lenalidomide, dexamethasone (dara-VRd) | NCCN 2026 preferred regimen for transplant-eligible newly diagnosed myeloma. Adds anti-CD38 monoclonal antibody; superior PFS vs. VRd alone. |
| Isatuximab, bortezomib, lenalidomide, dexamethasone (Isa-VRd) | NCCN 2026 preferred regimen for transplant-eligible newly diagnosed myeloma. Alternative to dara-VRd with anti-CD38 mechanism. |
| Lenalidomide and dexamethasone (Len-Dex) | Standard regimen for transplant-ineligible newly diagnosed myeloma and older/frail patients. Simpler, oral, continuous therapy with good efficacy and tolerability. |
| Lenalidomide plus rituximab | Used in follicular lymphoma and marginal zone lymphoma (previously treated). Combines anti-CD20 antibody with immunomodulatory effect. |
| Carfilzomib, lenalidomide, dexamethasone (KRd) | Alternative proteasome inhibitor-based backbone. Used in relapsed myeloma or when bortezomib is not tolerated. |
If lenalidomide stops working
Resistance can develop through several mechanisms. Understanding why lenalidomide failed guides selection of next-line therapy.
| Primary resistance and lenalidomide refractoriness | If disease progresses within 60 days of finishing lenalidomide or doesn't respond at all, lenalidomide-refractory disease is declared. Requires immediate switch to non-IMiD therapy. |
| Cereblon mutations and IKZF1 dysregulation | Rarely, mutations in CRBN or altered IKZF1/IKZF3 expression can render lenalidomide ineffective. These resistance mechanisms inform next therapy selection. |
| Next-line options in relapsed/refractory myeloma | Proteasome inhibitors (carfilzomib, ixazomib), second anti-CD38 antibody (if first failed), BCMA-directed therapy (CAR-T, teclistamab), bispecific antibodies, or checkpoint inhibitors. |
| Next-line options in MDS and lymphoma | In MDS with del(5q), hypomethylators (azacitidine, decitabine) or other IMiDs may be tried. In lymphoma, rituximab escalation, chemoimmunotherapy, or clinical trials considered. |
Cost of lenalidomide by country
Lenalidomide is among the most expensive cancer drugs globally. Generic approval in 2026 is beginning to lower prices, especially in countries with generic manufacturing capacity.
| India | Generic lenalidomide costs approximately $130-200 USD per month (or INR 600-800 per bottle from manufacturers like Natco, Dr. Reddy's). Extremely affordable compared to global prices. Multiple manufacturers ensure competition and low cost. |
| USA | Branded Revlimid: $24,000-25,000/month. Generic lenalidomide (FDA approved Jan 2026): $8,000-12,000/month. Patient assistance programs available. Most insurance plans cover but copays can be $1,000-3,000/month. |
| UK and Europe | NHS coverage and national insurance systems typically cover lenalidomide with minimal patient cost. Private pay costs similar to USA. Some countries negotiate lower prices than US market. |
| China | Imported branded lenalidomide costs approximately CNY 470/month ($65-70 USD equivalent). Limited generic availability. Hospital formularies and insurance coverage vary significantly. |
| Canada and Australia | Public healthcare systems cover cost. Private pay similar to USA. Generic now available at lower cost than brand. |
Availability of lenalidomide globally
Lenalidomide is widely available globally through regulated channels. Generic approval in 2026 expands access significantly. Availability depends on country approval status, local manufacturing, and supply chain.
India
Generic lenalidomide widely manufactured and available (Natco, Dr. Reddy's, others) through licensed pharmacies in major cities. Very affordable, with named patient programs also available.
USA
Branded Revlimid is available through specialty pharmacies; generic (Amneal, Teva, others) requires REMS enrollment. Insurance or manufacturer copay assistance is often needed.
China
Branded lenalidomide available in major cancer hospitals; imported and relatively expensive (CNY 470/month approx). Limited generic manufacturing. Hospital formulary access varies. Insurance coverage inconsistent. Supply sometimes constrained.
Europe (UK, Germany, France)
Branded and generic lenalidomide available through public healthcare systems. NHS coverage in UK. National insurance systems typically cover cost. Private pay available. Pricing negotiated at national level; generally lower than USA.
Southeast Asia (Philippines, Thailand, Vietnam)
Branded lenalidomide available through selected hospitals; imported and expensive. Generic penetration low. Import duties and limited supply increase costs. Coverage variable by country and insurance status.
Lenalidomide in current clinical trials
Lenalidomide continues to be studied in new combinations, new diseases, and refined sequencing strategies for blood cancers.
| Combination trials with bispecific antibodies | Studies investigating lenalidomide combined with BCMA-targeting or other bispecific antibodies in relapsed/refractory myeloma. Goal is to improve response rates and overcome resistance mechanisms. |
| Subcutaneous formulations and new routes | Research into less frequent dosing schedules and alternative administration routes to improve tolerability and patient convenience. |
| Lenalidomide in solid tumors | Emerging trials in lenalidomide-sensitive solid cancers (e.g., renal cell carcinoma). Extending IMiD efficacy beyond traditional blood cancers. |
| De-escalation and risk-adapted strategies | Trials exploring whether favorable-risk myeloma patients can receive shorter, less intensive lenalidomide regimens without compromising outcomes. |
Your treatment journey with lenalidomide
Diagnosis and molecular testing
Organ function assessment
Treatment plan and REMS enrollment
Starting treatment
Early monitoring (weeks 1-8)
Response assessment and ongoing treatment
Long-term monitoring and maintenance
If resistance or intolerance develops
Questions to ask your oncologist about lenalidomide
- Is lenalidomide appropriate for my specific disease type and stage?
- Will I receive lenalidomide alone or in combination with other drugs?
- What is my starting dose and how will it be adjusted?
- What blood tests will I need and how often?
- Do I need blood clot prevention, and if so, which medication?
- What side effects should I report immediately versus manage at home?
- What happens if lenalidomide stops working or my disease progresses?
- Is generic lenalidomide available, and can I switch from branded Revlimid?
How CancerFax supports lenalidomide patients
CancerFax helps patients and families understand lenalidomide, navigate access, arrange specialist consultation, and explore treatment options across borders.
| Medical report review | Upload your pathology, cytogenetics, myeloma markers, or imaging. Our oncology team reviews and explains your results and what they mean for lenalidomide eligibility and expected response. |
| Specialist connection | We connect patients with hematologists and oncologists who specialize in myeloma, MDS, and lymphoma. Arrange second opinions from experts in lenalidomide-based regimens. |
| Generic sourcing and cost navigation | We help identify legitimate, quality-assured generic lenalidomide suppliers and explain affordability options in India, China, and other countries. Substantial cost savings possible. |
| International access coordination | For patients seeking treatment in China or other international cancer centers, CancerFax coordinates hospital selection, treatment planning, travel logistics, and follow-up care communication. |
| Clinical trial matching | If lenalidomide stops working or side effects are intolerable, we help identify clinical trials testing new combinations, bispecific antibodies, or CAR-T therapy relevant to your disease status. |
Frequently asked questions about lenalidomide
Common questions from patients and caregivers
Lenalidomide is an immunomodulatory drug (IMiD), not chemotherapy. It works by modifying immune signaling and causing degradation of proteins that support cancer cells. This targeted approach means hair loss, severe nausea, and mouth sores are uncommon. It is taken as an oral capsule at home, not as an IV infusion in hospital.
Response timing depends on your cancer type. In multiple myeloma, most patients see improved disease control within 2-4 months on combination therapy. In MDS with del(5q), transfusion independence may take 6-8 weeks. In lymphoma, response is typically evaluated by CT scan at 2-3 months. Your oncologist will explain your specific response milestones.
Lenalidomide has moderate drug interactions but fewer than some other cancer drugs. It is metabolised in the kidneys, not the liver, so CYP enzyme interactions are less common. Avoid carbamazepine and rifampicin (inducers). Warfarin interaction is significant — low-molecular-weight heparin is preferred if anticoagulation is needed. Show your oncologist and pharmacist a complete list of all medicines, supplements, and herbal products.
Yes — generic lenalidomide approved by the FDA in 2026 (Amneal) is bioequivalent to Revlimid. The active ingredient, dose, and clinical efficacy are identical. Multiple real-world studies confirm equivalent outcomes between generic and branded versions. Generic lenalidomide is endorsed by NCCN and all major oncology guidelines.
If disease progresses while on lenalidomide, your oncologist will review the pattern of progression and consider resistance testing if applicable. Next-line options depend on your disease type: in myeloma, newer bispecific antibodies, BCMA-directed therapy (CAR-T), or proteasome inhibitors; in lymphoma, combination with rituximab or checkpoint inhibitors. A second opinion is often helpful to explore all options.
No. Lenalidomide is a known teratogen — it can cause severe birth defects or miscarriage if taken during pregnancy. It is distributed under a strict Risk Evaluation and Mitigation Strategy (REMS) program requiring pregnancy tests, contraception, and patient agreements. Do not breastfeed while taking lenalidomide. If planning pregnancy, discuss with your oncologist — stopping may be an option for some patients in sustained remission.
Common side effects include fatigue, low blood counts, diarrhea or constipation, rash, and muscle cramps. These are usually manageable with dose adjustments, supportive care (blood transfusions, growth factors), and dietary changes. Serious side effects like blood clots and severe infections require urgent medical attention. Your team will monitor blood counts regularly and adjust the dose based on results and tolerability.
Cost varies dramatically by country and brand. In the USA, branded Revlimid is about $25,000/month; generic is now available but still $8,000-12,000/month. In India, generic lenalidomide costs $130-200/month. In China, costs are around CNY 470/month. CancerFax can help you explore access options, patient assistance programs, and international sources if cost is a barrier to treatment.